The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a negative opinion for delamanid for the treatment of pulmonary multidrug-resistant tuberculosis in combination with an optimised background regimen according to WHO guidelines in patients.

Otsuka's response to TB CAB letter regarding pharmacokinetic studies, paediatric studies, and compassionate use of delamanid.